drugset / Trial / NCT06088979
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Timeline
- Start
- 2024-02-19
- Primary completion
- 2026-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PACIBEKITUG | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | PACIBEKITUG | Monoclonal antibody | 50 mg | Subcutaneous |